A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.
Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of theEGFRdeletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas.
Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center; Durham, NC USA ; Department of Pathology; Duke University Medical Center; Durham, NC USA.
Vidyalakshmi
V
Chandramohan
Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center; Durham, NC USA ; Department of Pathology; Duke University Medical Center; Durham, NC USA.
Darell D
DD
Bigner
Pseudomonasexotoxin; bispecific antibody; brain tumors; convection-enhanced delivery; glioma-associated antigens